Kelly, who made several key hires at the CDRH and helped negotiate the last user fee agreement, announced his departure in a ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...